Abstract:e16590 Background: Neoadjuvant cisplatin-based chemotherapy remains the standard systemic therapy for cisplatin-eligible patients undergoing radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC). However, its application is constrained due to suboptimal efficacy and considerable safety concerns. The combination of immunotherapy with antibody-drug conjugates is being actively explored as an innovative approach to neoadjuvant therapy for MIBC. Disitamab vedotin (DV) has demonstrated encouraging outcomes in HER2-positive locally advanced or metastatic urothelial carcinoma. Thereby our study aimed to assess the effectiveness and safety of DV combined with toripalimab (PD-1 inhibitor) as neoadjuvant therapy in patients with HER2-expressing MIBC followed by either selective bladder preservation or RC. Methods: This retrospective, single-arm study included patients with histopathologically diagnosed MIBC (T2-4N0-1M0). The regimens comprised DV at a dose of 2.0 mg/kg and toripalimab at 3.0 mg/kg, both delivered intravenously biweekly. Following the neoadjuvant therapy, patients achieving a complete response (CR) or downstaged to non-MIBC were given the choice of either RC or opting for bladder-sparing. Patients not meeting the criteria underwent RC. The primary endpoint was the complete clinical response (cCR) rate. Secondary endpoints included bladder intact disease-free survival (BI-DFS), pathological downstaging (pDS) rate, and safety. Furthermore, we investigated the correlation between cCR and HER2 expression levels. Results: This study enrolled 47 patients between June27, 2022, and October 20, 2023. The median age was 66.0 years, with male representation at 85.1%. Baseline molecular profiling revealed varying levels of HER2 expression: HER2 IHC 3+ (17.0%), HER2 IHC 2+ (48.9%), and HER2 IHC 1+ (34.0%). The median number of treatment cycles administered was 4 ( 3.0-9.0). Remarkably, out of 47 patients, 29 achieved cCR (61.7%). This cCR rate positively correlated with the levels of HER2 expression. Additionally, 37 of the 47 patients achieved pDS (78.7%). Post neoadjuvant therapy, 30 patients opted for bladder-preserving and the rest underwent RC. Over a median follow-up period of 8.0 months (3.0-14.0), the median BI-DFS was not reached, with a 1-year BI-DFS rate of 100%. The most common TRAEs of any grade included anorexia (68.1%), peripheral sensory neuropathy (66.0%), and fatigue (61.7%). Grade 3 or worse TRAEs occurred in 25% of patients, primarily involving anemia, elevated ALT, and fatigue. Conclusions: The combination of DV and Toripalimab as neoadjuvant therapy demonstrated notable efficacy and a manageable safety profile in patients with HER2-expressing MIBC followed by either selective bladder preservation or RC.

Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer

Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis

Neoadjuvant cisplatin-based chemotherapy in nonmetastatic muscle-invasive bladder cancer: A systematic review and pooled meta-analysis to determine the preferred regimen

Effectiveness of dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin as compared to gemcitabine‐based regimens as neoadjuvant chemotherapy for oncologic outcomes in muscle‐invasive bladder cancer cases—Single‐center study in Japan

Neoadjuvant Chemoradiotherapy Followed by Radical Cystectomy for Muscle-Invasive Bladder Cancer: Analysis of Efficacy and Safety in 119 Patients

Efficacy and safety analysis of neoadjuvant chemotherapy combined with immunotherapy in patients with muscle-invasive bladder cancer

Neoadjuvant gemcitabine-cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial

Gemcitabine Plus Cisplatin Neoadjuvant Chemotherapy with Radical Cystectomy for the Treatment of Muscle Invasive Bladder Cancer: 9 Years Retrospective Analysis

703P Camrelizumab in Combination with Gemcitabine Plus Cisplatin As Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer

A phase II study of toripalimab combined with gemcitabine-cisplatin as neoadjuvant therapy for patients with muscle-invasive bladder cancer (MIBC).

Effectiveness of Neoadjuvent Chemotherapy with Gemcitabine and Cisplatin for Muscle Invasive Bladder Carcinoma

Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle‐invasive bladder cancer: A multi‐center, single‐arm, phase 2 study

Efficacy and Safety of Neoadjuvant Therapy with Disitamab Vedotin Plus Toripalimab in Treating Muscle Invasive Urothelial Bladder Cancer Followed by Selective Bladder-Preserving or Radical Cystectomy.

Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer

Neoadjuvant Therapy with Disitamab Vedotin in Treating Muscle-Invasive Bladder Cancer: A Case Report

Real-world study of chemotherapy plus immunotherapy versus chemotherapy alone as neoadjuvant treatment guided bladder-sparing therapy for localized muscle-invasive bladder cancer.

Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer.

Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy.

Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial

Bladder-sparing treatment for muscle-invasive bladder carcinoma: A single-center, single-arm clinical study of sequential neoadjuvant chemotherapy followed by tislelizumab neoadjuvant immunotherapy.

2375P Neoadjuvant Sintilimab Combined with Gemcitabine and Cisplatin (GP) for Muscle-Invasive Bladder Cancer (MIBC) Patients Followed by Selective Bladder Sparing Surgery